Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
L ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
L01 ANTINEOPLASTIC AGENTS
L01E PROTEIN KINASE INHIBITORS
L01EX Other protein kinase inhibitors
L01EX10 Midostaurin
D05029 Midostaurin (JAN/USAN/INN) <US>
USP drug classification [BR:br08302]
Antineoplastics
Molecular Target Inhibitors
Multitargeted Kinase Inhibitors, FLT3
Midostaurin
D05029 Midostaurin (JAN/USAN/INN)
Drug groups [BR:br08330]
Antineoplastic
DG01918 Tyrosine kinase inhibitor
DG01917 Receptor tyrosine kinase inhibitor
D05029 Midostaurin
Metabolizing enzyme substrate
DG01633 CYP3A/CYP3A4 substrate
DG02913 CYP3A4 substrate
D05029 Midostaurin
Target-based classification of drugs [BR:br08310]
Protein kinases
Serine/threonine kinases
AGC group
PRKCA
D05029 Midostaurin (JAN/USAN/INN) <US>
PRKCB
D05029 Midostaurin (JAN/USAN/INN) <US>
PRKCG
D05029 Midostaurin (JAN/USAN/INN) <US>
Receptor tyrosine kinases (RTK)
PDGFR family
PDGFR
D05029 Midostaurin (JAN/USAN/INN) <US>
KIT (CD117)
D05029 Midostaurin (JAN/USAN/INN) <US>
FLT3* (CD135) [HSA_VAR:2322v12322v2]
D05029 Midostaurin (JAN/USAN/INN) <US>
VEGFR family
VEGFR2 (KDR)
D05029 Midostaurin (JAN/USAN/INN) <US>
New drug approvals in the USA [br08319.html]
New molecular entities and new therapeutic biological products
D05029
New drug approvals in Europe [br08329.html]
European public assessment reports (EPAR) authorised medicine
D05029
New drug approvals in the USA, Europe and Japan [br08328.html]
Approval dates by FDA, EMA and PMDA
D05029
Drug metabolizing enzymes and transporters [br08309.html]
Drug metabolizing enzymes
D05029
Pharmacogenomic biomarkers [br08341.html]
Somatic variations in targeted cancer therapies
D05029